Fw: Ref.: (LML) ILEP’s Priorities World Leprosy Day 2026: Leprosy is curable, the real challenge is stigma

 

Leprosy Mailing List –  January 31,  2026

 

Ref.:  (LML) ILEP's Priorities World Leprosy Day 2026: Leprosy is curable, the real challenge is stigma

From: Pieter AM Schreuder, Maastricht, the Netherlands

 

Dear colleagues,

 

 

When looking for some information about World Leprosy Day 2026 I came across ILEP's website and was struck by the fact that an AI-generated overview was given of ILEP's priorities. Was this intentionally or has the ILEP website been hijacked by AI or is this the new normal? Does ILEP agree with this AI overview?

 

Ben Naafs made some comments in italics in brackets.

 

 

 

AI overview ILEP World Leprosy Day 2026

 

For World Leprosy Day 2026 (observed on January 25, 2026), international organizations, including those in the ILEP (International Federation of Anti-Leprosy Associations) network and the World Health Organization (WHO), are centering their messages on the theme: "Leprosy is curable, the real challenge is stigma". 

 

Key messages for 2026 focus on combining medical treatment with the dismantling of social barriers. 

 

Core Messages and Themes for 2026

• Stigma as the Primary Barrier: While leprosy (Hansen's disease) is easily curable (Ben Naafs: "only TT and BT") with Multi-Drug Therapy (MDT) and treatment is provided free of charge, the stigma associated with the disease causes social exclusion, loss of jobs, and delays in seeking treatment.
• "Real Challenge" Focus: The 2026 campaign highlights that even after a person is completely cured (Ben Naafs: "BL and LL are in remission not cured"), the social stigma can persist, necessitating a focus on human rights, dignity, and social inclusion.
• Education to End Stigma: The Global Appeal 2026, launched by the Sasakawa Leprosy (Hansen's Disease) Initiative and partners, emphasizes using education to replace fear with knowledge, aiming to end the 2,000-year-old prejudices against those affected. (Ben Naafs: "In order to remain trustworthy you have to tell the truth. People will not believe you, when you tells something that does not fit with what they see with their own eyes").
• Towards Zero Leprosy: The campaigns advocate for the "Zero Leprosy" strategy—aiming for zero infection, zero disability, and zero stigma and discrimination by 2030. 

Background

Established in 1954 by Raoul Follereau, World Leprosy Day is held annually on the last Sunday of January to raise awareness, honor those affected, and demand an end to discrimination. It coincides with the anniversary of Mahatma Gandhi's death to recognize his work with affected individuals.

 

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/0a7bd4a0-7afc-4d1f-8463-1faea555ef75n%40googlegroups.com.

Fw: Ref.: (LML) World Neglected Tropical Diseases Day

 

Leprosy Mailing List –  January 28,  2026

 

Ref.:  (LML) World Neglected Tropical Diseases Day 

From: Pieter Schreuder, Maastricht,, the Netherlands

____________________________________________________________________________

 

Dear colleagues,

 

Dr. Francesa Gajete (Manilla, the Philippines) pointed out to me that World Neglected Tropical Diseases Day is observed every year on 30 January. This year coming Friday.

From the WHO NTD website I copied the following text:

Neglected tropical diseases (NTDs) are a diverse group of conditions that still affect one billion people worldwide, primarily in vulnerable and underserved communities. Yet they are preventable, treatable, and can be eliminated. In 2024, around 1.4 billion people required interventions against neglected tropical diseases, a 36% decrease from 2010. As of early 2026, 58 countries have successfully eliminated at least one NTD—demonstrating significant progress toward the WHO's global target of 100 countries reaching elimination by 2030.

However, this hard-won progress is now at risk. Deep cuts in official development assistance for global health, particularly for NTD programs, threaten to stall or reverse gains and negatively impact the lives of affected communities.

Proven, low-cost tools exist, such as preventive chemotherapy—which delivers an estimated $25 in economic benefits for every $1 invested—yet NTDs remain among the most underfunded areas in global health.

On World NTD Day 2026, we must answer the call to unite, act, and eliminate NTDs, building a safer and more resilient world for everyone. We urge countries to invest in better tools, systems, approaches, and partnerships so that domestically owned and financed NTD programmes are sustainable. We call on partners to continue to honor commitments, protect hard-earned gains, unlock innovative financing, and implement new approaches.

 

Let us celebrate country-led successes, champion innovation in diagnostics and treatment, and secure the leadership and resources needed to ensure NTD elimination remains one of the most achievable and equitable goals in global health.

WHO plays a central role in this global effort—setting norms and strategies, coordinating partners to monitor global progress, supporting Member States in overcoming technical and programmatic challenges, and guiding the collective effort to achieve the 2030 control, elimination and eradication targets.

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/51c96846-b7c0-4aa6-9483-677a02a3a7dbn%40googlegroups.com.

Fw: Ref.: (LML) R.I.S.E. For ZERO: Join the Webinar to End Leprosy Stigma. January 28, 2026

 

 

 

Leprosy Mailing List –  January 27,  2026

 

Ref.:  (LML) R.I.S.E. For ZERO: Join the Webinar to End Leprosy Stigma. January 28, 2026

From: Culion Foundation, Quezon City, Philippines

______________________________________________________________________     

Greetings Partners and Friends, 

We are pleased to invite you to attend our upcoming webinar entitled "R.I.S.E. For ZERO:               Restoring Identity, Stopping Exclusion, Ending Leprosy Stigma to Achieve Zero Leprosy."

This webinar aims to promote awareness, understanding, and collective action toward eliminating leprosy-related stigma and discrimination, while highlighting the importance of restoring dignity, inclusion, and identity among affected individuals and communities.

🗓️Date: January 28, 2026
🕐Time: 1:00 PM – 3:00 PM
📍Platform: Zoom and Facebook Live (Culion Foundation, Inc. Facebook Page)

Register now as slots are limited.

Registration Link: https://forms.gle/x5eUsuUy95pBxctm6

Culion Foundation, Inc. Official Facebook Page: facebook.com/culionfoundation

Your participation in this discussion is needed as we work toward achieving a Leprosy-Free Philippines.

For questions or concerns, please contact us.

 

Thank you, and we look forward to your participation. 

 

 

Corporate Affairs Unit - Culion Foundation, Inc.

No. 16 Mother Ignacia Ave. cor., Roces Ave.

Quezon City, Philippines 1103

T: (632) 8374.2026 | E: cfi@culionfoundation.org.ph

www.culionfoundation.org.ph

 

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

 

 

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/fe4ec456-9278-4da4-af59-28c0c3a8d99en%40googlegroups.com.

Fw: Ref.: (LML) Comments on GPZL “MDT Last-Mile Supply Chain Survey” – scope, transparency, and SDR-PEP question

 

Leprosy Mailing List –  January 27,  2026

 

Ref.:  (LML) Comments on GPZL "MDT Last-Mile Supply Chain Survey" – scope, transparency, and SDR-PEP question

From: Claudio Salgado, Pará, Brazil

____________________________________________________________________________

 

 

Dear colleagues,

I am writing to share some concerns regarding the Global Partnership for Zero Leprosy (GPZL), Global Survey "Leprosy MDT Last-Mile Supply Chain Survey", recently circulated by e-mail and available at https://www.surveymonkey.com/r/X7FN2JQ.

First, I would like to acknowledge that mapping "last-mile" bottlenecks in MDT availability is a relevant initiative. However, after reading the questionnaire, I believe there are important methodological and practical limitations that should be addressed, so that the survey can better reflect the real-world needs of leprosy programs and clinicians.

1) The survey does not clearly define its ultimate purpose and use of results

The introduction mentions that the survey will help identify bottlenecks and "develop practical, evidence-based solutions and recommendations." However, it is not clear: i) who will lead the analysis and governance of the results; ii) what decisions or investments the results will directly inform; iii) whether findings will be publicly available and in what format; and iv) how participating programs will receive feedback and support.

For an initiative intended to guide supply-chain decisions, transparency about outputs, intended actions, and accountability is essential.

2) The survey focuses exclusively on MDT blister packs and ignores substitute/alternative regimens

While MDT blister pack availability is obviously central, the survey's scope is limited to blister packs and logistics for standard MDT.

In clinical practice, especially from the perspective of a hansenologist (leprologist), substitute regimens and alternative drugs are increasingly necessary (for example, resistance, intolerance, adverse events, drug–drug interactions, and complex clinical scenarios).

A supply-chain discussion that excludes the availability (or lack) of substitute drugs risks producing recommendations that are disconnected from real clinical care and program resilience.

3) The last question introduces SDR-PEP, which is not MDT and is scientifically controversial

The final question asks whether, "as your program scales up leprosy prevention," the supply chain for single-dose rifampicin post-exposure prophylaxis (SDR-PEP) faces similar bottlenecks as MDT.

This is problematic for two reasons:
Conceptual scope drift: SDR-PEP is not MDT, and introducing it in an MDT supply survey (as the final question) may bias the narrative toward "scale-up prevention" as an assumed program direction, instead of a debated policy choice.

 
Safety and effectiveness are not settled: SDR-PEP remains controversial in outcomes, and there is evidence raising concern about possible adverse consequences. In particular, an article recently contributed to a quantitative analysis showing a substantial increase in visible deformity at diagnosis following chemoprophylaxis implementation in an endemic setting, with a strong statistical association between the number of contacts who received chemoprophylaxis and visible deformity detected in the subsequent year (p=0.0002; R²=0.9132).
This paper, available at: https://www.ijl.org.in/article-detail/97/544, argues that potential harms should be better elucidated before expanding brief chemoprophylaxis strategies.

In summary, if GPZL wishes to obtain a robust map of "last-mile" MDT barriers, the survey should be strengthened by:
1) clarifying the purpose, governance, and expected outputs.
2)  incorporating the reality of substitute regimens and non-standard MDT needs, and
3)  avoiding conflation between MDT supply and SDR-PEP scale-up, particularly given ongoing scientific debate.

I am sharing these comments in the spirit of strengthening the initiative and aligning it with the realities of both field programs and clinical practice.

Kind regards,

Claudio Salgado

 

====================================================

Claudio Guedes Salgado, MD, PhD

Full Professor

Institute of Biological Sciences
Federal University of Pará

Former President of Brazil Hansen's Disease Society (SBH), 2018-2023

International relations advisor for the SBH

Elected Councillor for the Americas 2025–2028 International Leprosy Association (ILA)

Dermato-Immunology Lab

Av. João Paulo II, 113
Bairro: Dom Aristides
Marituba - Pará - Brasil
CEP: 67200-000
Phone: +55-91-3201-7033

Cell phone: +55-91-991465641
E-mails: csalgado@ufpa.br and claudioguedessalgado@gmail.com

Lattes CV (Brazil format): http://lattes.cnpq.br/2310734509396125

ORCID ID: https://orcid.org/0000-0003-3961-7764  

LinkedIn: https://www.linkedin.com/in/claudio-guedes-salgado/
Instagram: https://www.instagram.com/claudiosalgado/

Facebook: https://www.facebook.com/claudioguedessalgado

Map to the Lab: https://goo.gl/maps/7omyd54wy7z  

===================================================

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/5a501c86-2913-4437-ae3c-3b2a1d87fd95n%40googlegroups.com.

Fw: (LML) Skin-related neglected tropical diseases

                    Leprosy Mailing List –  January 26,  2026

 

Ref.:  (LML) Skin-related neglected tropical diseases

From: Ben Naafs, Munnekeburen, the Netherlands

____________________________________________________________________________

 

Dear colleagues,

 

Some time ago the World Health Organization (WHO)  released  an enhanced version of its Skin NTDs App, a valuable tool designed to assist front-line health workers in diagnosing and managing skin-related neglected tropical diseases (skin NTDs). The updated App is available free of charge on both Android and iOS devices.

At least ten of the diseases included in World Health Organization's (WHO) list of neglected tropical diseases can present with manifestations on the skin. These so-called skin NTDs include Buruli ulcer, cutaneous and post-kala azar dermal leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis, mycetoma, yaws, chromoblastomycosis and other deep mycoses, and scabies and other ectoparasites. Due to their common manifestations, skin NTDs can be targeted with similar case detection and disease management approaches. Additionally, skin-related NTDs are often associated with lifelong disabilities, stigma and mental health problems. These commonalities, and the frequent co-endemicity of these diseases in many regions, present opportunities for the integration of interventions (InfoNTD)

Implementing the integrated control and management of skin neglected tropical diseases

In the context of skin NTDs, integration is defined as the implementation of two or more activities simultaneously in the same communities in order to optimize the use of limited resources (WHO):

•   = - Skin NTDs are often co-endemic in many countries, districts, and communities. They may have same common manifestations and approaches to detection. Examination of the skin therefore serves as an opportunity to identify multiple conditions in a single intervention and also to improve case detection. For example, post-kala-azar dermal leishmaniasis can be detected during leprosy case detection campaigns, or vice versa.

            - - Skin NTDs are often underreported or are not included in routine surveillance systems. An integrated approach offers opportunities for active screening in communities and in schools.

•    - -Combined activities to control skin NTDs improves understanding of their total related burden and of the need for greater advocacy and optimal and efficient use of human, material and financial resources.

 

Ben

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/0656ebed-6c7a-47d2-b2e8-7853feb205f0n%40googlegroups.com.

Fw: Ref.: (LML) Outcast: A History of Leprosy, Humanity and the Modern World

 

Leprosy Mailing List –  January 25,  2026

 

Ref.:  (LML) Outcast: A History of Leprosy, Humanity and the Modern World

From: Ben Naafs, Munnekeburen, the Netherlands

____________________________________________________________________________

 

 

Dear Pieter,

 

Maria Angela Trindade (Bauru, Brazil), made me aware of an interesting book: "Outcast: A History of Leprosy, Humanity and the Modern World"

By Oliver Basciano,  printed by Faber and Faber, 2025 pp 320, £20·00

 

There is a good review by Anna Greenwood in the Lancet January 2026 (see attached file)

 

With kind regards

Ben

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/6140bb51-5110-4b65-a9e3-66428df8e76fn%40googlegroups.com.

Fw: Ref.: (LML) World Leprosy Day on the last Sunday of January

 

Leprosy Mailing List –  January 22 ,  2026

 

Ref.:  (LML) World Leprosy Day on the last Sunday of January

From: Francesca Gajete, Manila, Philippines

____________________________________________________________________________

 

Dear Pieter,

 

May I share this WHO publication on my mail…kindly help me get this thru LML for our colleagues…

 

Wednesday, 21 January 2026

WHO renews commitment to a leprosy-free world, spotlighting partnership and progress ahead of
World Leprosy Day

https://www.who.int/news/item/21-01-2026-who-renews-commitment-to-a-leprosy-free-world--spotlighting-partnership-and-progress-ahead-of-world-leprosy-day/

Geneva, 21 January 2026 - Access to treatment for leprosy is essential to global efforts to eliminate leprosy, says the World Health Organization (WHO) ahead of World Leprosy Day, to be observed on 25 January.

Leprosy is an infectious disease caused by a type of bacteria, Mycobacterium leprae, and is one of the oldest diseases known to humanity. The disease predominantly affects the skin and peripheral nerves. Left untreated, the disease may cause progressive and permanent disabilities and causes stigma and social isolation However, the disease can be cured with multidrug therapy (MDT).

Efforts to eliminate leprosy have been leading to reductions in the number of new cases in many areas; of the 188 countries, areas or territories that submitted data in 2024, 55 reported zero cases. But still 172 717 new cases were detected worldwide and reported to WHO in the same year.

Many partners, including pharmaceutical companies such as Novartis, have been strong supporters of efforts to eliminate leprosy. WHO has collaborated with Novartis since 2000 to provide MDT and clofazimine, free of cost, to all leprosy patients worldwide. This partnership remains one of the most sustained pharmaceutical donation programmes in global health.

Marking 25 years of partnership, WHO and Novartis have extended a Memorandum of Understanding (MoU) for an additional 5 years (2026−2030). The extension makes provision for continued supply of MDT and also includes funding for procurement and distribution of single dose rifampicin (SDR) for post-exposure prophylaxis (PEP).

"The unwavering commitment of partners like Novartis over the past quarter-century has been foundational to the progress made against leprosy," said Dr Jeremy Farrar, WHO Assistant Director-General for Health Promotion, Disease Prevention and Care. "Their steadfast support in ensuring free access to treatment has helped transform millions of lives and moved us closer to a world free from this ancient disease. This enduring collaboration exemplifies the power of global solidarity in health – a reminder that, together, we can overcome even the oldest and most entrenched health challenges when science, equity, and partnership align."

Availability of free MDT has made it possible to cure the disease, prevent disabilities, mitigate stigma, and has enabled affected individuals to continue working and leading normal lives. Additionally, clofazimine has ensured the treatment of lepra reactions, which are characterized by sudden, severe inflammatory episodes, leading to disabilities, if left untreated.

"Leprosy is one of the oldest infectious diseases known to humanity and combatting it has been part of our company's history since discovering the first effective cure," said Dr Lutz Hegemann, President of Global Health at Novartis. "Over the last 25 years, we have reached millions of patients together with WHO, and we are committed to going further to pursue our vision of a world free of leprosy."

While significant progress has been made, sustaining and building on this momentum requires political commitment, community engagement and continued collaboration and partnership.

The theme for this year's World Leprosy Day is "Leprosy is curable, the real challenge is stigma".

This year also marks the 25^th anniversary of Mr Yohei Sasakawa's work as the WHO Goodwill Ambassador for Leprosy Elimination. He said, "One of the most stubborn challenges that I encounter on my travels is the social stigma attached to leprosy, which can be more problematic than the disease itself, and which can persist beyond the end of treatment. This is particularly true for people who have been left with residual disabilities as a result of leprosy. They may face various forms of discrimination, including forced divorce, lost educational opportunities and unfair dismissal. Even after being cured, they endure the unending pain of social exclusion."

As leprosy is one of the target diseases under the broader umbrella of Neglected Tropical Diseases (NTDs), this work also supports the unified global effort towards a world free of NTDs. Learn more about the collective action and join our campaign on World NTD Day 2026 on 30 January.

Notes for editors

The NTD Roadmap 2021-2030 aims at elimination of leprosy (interruption of transmission). The Global Leprosy Strategy 2021–2030 underpinning the Roadmap, shifts the paradigm beyond the achievement of 'elimination of leprosy as a public health problem' toward interruption of transmission and elimination of leprosy disease. Contact screening along with scale-up of preventive chemotherapy and mitigation of stigma and discrimination constitute key pillars of this strategy. Beyond working to ensure that every person affected by leprosy is detected early and treated promptly, WHO leads efforts to combat the discrimination that persons affected by leprosy too often face.

Related: WHO's work on leprosy

 

The Philippines is now gearing up promotions with our Government facilities, Partner Institutions, Patient Organizations and Partner CSOs for the promotion of WLD 2026 towards the attainment of GPZL 2030.

 

With kind regards,

 

Francesca

 

Dr Francesca Cando Gajete,MHA,FPLS

Member,International   Leprosy Association 

Trustee, Culion Fdtn Inc

Former National Leprosy   Control Program    Manager,Philippines 

 

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/0851c21b-f07f-4e7c-8246-89c50aae39a9n%40googlegroups.com.

Fw: Ref.: (LML) Mycobacterium leprae, Mycobacterium lepromatosis and Leprosy Studies - Special Issue

 

 

Leprosy Mailing List –   January 21,  2026

 

Ref.:  (LML) Mycobacterium leprae, Mycobacterium lepromatosis and Leprosy Studies - Special Issue

From: Cleverson Teixeira Soares, Patrícia Sammarco Rosa and  Bruno de Carvalho Dornelas, Instituto Lauro de Souza Lima, Bauru, Brazil

____________________________________________________________________________

 

Dear Pieter;

 

I hope you are doing fine and wish you a happy 2026!

 

Could you please help us promoting this special issue again?

 

https://www.mdpi.com/si/230126

 

Special Issue Information

Dear Colleagues,

The Special Issue entitled "Mycobacterium leprae, Mycobacterium lepromatosis and Leprosy Studies" aims to present recent research on a wide range of topics related to leprosy, a complex disease that mainly affects people living in developing countries. People exposed to Mycobacterium leprae or Mycobacterium lepromatosis may develop leprosy.

During the course of the disease, reaction phenomena typical of leprosy often occur, known as type 1 (T1R) and type 2 (T2R). These phenomena aggravate the disease and can cause significant and permanent sequelae. Little is known about the pathophysiological mechanisms of leprosy and its reaction phenomena. In addition, factors inherent to the bacilli and its interaction with the human host, such as energy resources and escape mechanisms, are slowly being revealed.

New studies are important to elucidate the pathophysiology of leprosy and, above all, to bring new approaches to the prevention and treatment of leprosy and leprosy reactions. We encourage the submission of clinical, translational, and basic research on leprosy. Some of its focal points include, but are not limited to, the following:

1. Serum or tissue markers that may be related to the diagnosis of the disease and reactional episodes.
2. Therapeutic approaches with commercially known drugs or new drug targets.
3. Clinical studies evaluating the risks of triggering reactional phenomena.
4. Metabolomic, transcriptomic, or proteomic profiles that correlate with the leprosy clinical forms and reactional phenomena.

 

Reviews, original research, and communications will be welcome.

Dr. Cleverson Teixeira Soares
Dr. Patrícia Sammarco Rosa
Dr. Bruno de Carvalho Dornelas
Guest Editors

 

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/7e46c396-a858-4770-88d4-e62bacfbc47an%40googlegroups.com.

Fw: Ref.: (LML) Deadline approaching: calls for proposals | Save the date: Spring Meeting 2026 | Research spotlight

 

 

Leprosy Mailing List –    January 21,  2026

 

Ref.:  (LML) Deadline approaching: calls for proposals | Save the date: Spring Meeting 2026 | Research spotlight

From: LRI, Amsterdam, the Netherlands

____________________________________________________________________________

Dear colleagues,

 

 

The LRI Secretariat wishes you a happy New Year! We are excited to share this first newsletter of 2026 which features the reminder for the research proposals submission deadline, LRI Spring Meeting dates and a Research spotlight.

 

 

Deadline for research proposal submissions approaching

There is only one week left to submit your Letter of Intent for the following LRI Calls for proposals:

• LRI Flagship grant (projects starting in 2027)
• RESILIENTD grant, in collaboration with Anesvad Foundation (projects starting in 2027)

The submission deadline for both calls is Friday, 23 January, at 17:00 CET. After this time, the portal will close, so please ensure your Letter of Intent is submitted on time. 
 

We look forward to receiving your research ideas. Best of luck to all applicants!

 

Submit your Letter of Intent

 

LRI Spring Meeting 2026 – Save the dates
 

The LRI Spring Meeting is an annual event that brings together researchers from LRI-funded projects, members of the LRI Scientific Review Committee and Steering Committee, as well as LRI partners. More than 35 researchers will present project progress updates and results during this year's edition, which will take place online on 9 and 10 April (afternoons CEST), so be sure to mark your calendars.

The online event is open to everyone interested in leprosy research and is free of charge.

Updates on the event and registration will be provided through our newsletter, website, and LinkedIn channel in due course.

 

 

Research spotlight - Skin Health Programme in a Penitentiary (SHEPP)
 

Under the RESILIENTD grant, the Skin Health Programme in a Penitentiary (SHEPP) launched in 2025 to strengthen the detection and management of skin-related NTDs at Kumasi Central Prison in Ghana. Working closely with incarcerated individuals, prison staff, and affected individuals, the project is co-designing a tailored skin health education programme, conducting screenings, and exploring how social determinants shape disease patterns in prison settings.
 

Initiatives like SHEPP demonstrate how research, community engagement, and system-level action can improve skin health and living conditions for vulnerable populations. However, as highlighted by El País, overcrowded prisons and similar settings continue to face significant challenges—underscoring the urgent need for further research and action.
 

Learn more about the project here and read the El País article here.
 

This work may also inspire new research ideas for the open RESILIENTD call. Congratulations to the research team—we look forward to hearing more at the LRI Spring Meeting.

We also thank our partner Anesvad Foundation for supporting this important work, and El País for its insightful reporting that helps bring visibility to these critical issues.

 

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/a884f4d4-a50c-465e-809a-c1682bc0b43fn%40googlegroups.com.